Atriva Therapeutics GmbH

Atriva Therapeutics GmbH is a clinical-stage biopharmaceutical company at the forefront of antiviral drug innovation, dedicated to developing a groundbreaking antiviral therapy platform. Atriva Therapeutics focuses on combating severe respiratory and systemic diseases resulting from RNA viruses, such as influenza and COVID-19, addressing critical unmet medical needs.

Operating from its headquarters in Planegg/Martinsried, Bavaria, at Am Klopferspitz 19, 82152, DE, Atriva Therapeutics is pioneering host-targeting antiviral therapies. This innovative approach minimizes the likelihood of viral resistance, offering a significant contribution to global pandemic preparedness. The company’s lead product, zapnometinib (ATR-002), is a first-in-class, host-targeting agent designed to inhibit viral replication and positively modulate the body’s immune response to RNA viruses.

With a strong commitment to scientific excellence and innovation, Atriva Therapeutics GmbH continues to advance its research and development efforts. To further explore partnership opportunities and discover more about Atriva Therapeutics, we invite you to connect with us. Company management is actively working to enhance our showcase with comprehensive information and product listings. We encourage the manager at Atriva Therapeutics GmbH to create a customized and exclusive company showcase and product listing on our platform to highlight your cutting-edge advancements in biotechnology.